glp 1 who makes it Market Overview: GLP-1 Agonists and the Obesity Market | Blog The GLP-1 Era: Why These

Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks

While these drugs have gained increased attention in the past decade, GLP-1, as a hormone, was first identified in the eighties

Preliminary research suggests the peptide stimulates proteoglycan synthesis in cartilage, which may benefit osteoarthritis (Metabolic Pharmaceuticals, 2010)

This physiological effect, while not necessarily harmful, may contribute to the sensation of heart palpitations reported by some patients

Official guidance from UK health authorities The National Institute for Health and Care Excellence (NICE) recommends GLP-1 drugs for patients with type 2 diabetes or with a very high BMI 12

however, this isn't directly linked to significant weight loss